CG Oncology, Inc.
Developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer.
CGON | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 400 SPECTRUM CENTER DRIVE, 92618 IRVINE
- Website:
- https://www.cgoncology.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes oncolytic immunotherapies. The company is focused on creating a potential backbone, bladder-sparing therapeutic for patients with bladder cancer, particularly Non-Muscle Invasive Bladder Cancer (NMIBC). Its lead product candidate is cretostimogene grenadenorepvec, an investigational engineered oncolytic immunotherapy designed to be a bladder-saving treatment. The therapeutic has received FDA Fast Track designation and is being evaluated in clinical trials as both a monotherapy and in combination with other therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CG Oncology, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CG Oncology, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CG Oncology, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
